849675-87-2

Encequidar mesylate (HM30181A mesylate) 是竞争性有效的 P-糖蛋白抑制剂。

Encequidar (HM30181A) 是一种选择性 P-糖蛋白抑制剂。

HM-30181 mesylate monohydrate 是一种口服 P-糖蛋白 (P-gp) 抑制剂，用于提高 P-gp 底物药物的口服生物利用度。

Encequidar, also known as HM-30181, is an oral P-glycoprotein (P-gp) inhibitor developed to enhance the oral bioavailability of P-gp substrate drugs. Encequidar showed the highest potency (IC(50)=0.63nM) among several MDR1 inhibitors, including cycloporin A, XR9576, and GF120918, and effectively blocked transepithelial transport of paclitaxel in MDCK monolayers (IC(50)=35.4nM). Encequidar is currently under clinical trials.